Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara A Byron

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Seminars in Oncology|November 13, 2003
Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancerSara A Byron, Douglas Yee
Cancer Treatment and Research|June 19, 2019
Genomics-Enabled Precision Medicine for CancerAlison Roos, Sara A Byron
Future Oncology (London, England)|February 27, 2009
FGFR2 as a molecular target in endometrial cancerSara A Byron, Pamela M Pollock
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2012
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cellsSara A Byron, David C Loch, Pamela M Pollock
Anti-Cancer Drugs|October 13, 2012
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenograftsNicole A Doudican, Sara A Byron, Pamela M Pollock, et al.
Molecular Cancer Research : MCR|September 30, 2008
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2Yasir H Ibrahim, Sara A Byron, Xiaojiang Cui, et al.
Nature Reviews. Genetics|March 22, 2016
Translating RNA sequencing into clinical diagnostics: opportunities and challengesSara A Byron, Kendall R Van Keuren-Jensen, David M Engelthaler, et al.
Molecular Cancer|October 9, 2012
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusSara A Byron, David C Loch, Candice L Wellens, et al.
Gynecologic Oncology|January 29, 2010
FGFR2 mutations are rare across histologic subtypes of ovarian cancerSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Plos One|March 3, 2012
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological featuresSara A Byron, Michael Gartside, Matthew A Powell, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Seminars in Oncology|November 13, 2003
Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancerSara A Byron, Douglas Yee
Cancer Treatment and Research|June 19, 2019
Genomics-Enabled Precision Medicine for CancerAlison Roos, Sara A Byron
Future Oncology (London, England)|February 27, 2009
FGFR2 as a molecular target in endometrial cancerSara A Byron, Pamela M Pollock
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2012
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cellsSara A Byron, David C Loch, Pamela M Pollock
Anti-Cancer Drugs|October 13, 2012
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenograftsNicole A Doudican, Sara A Byron, Pamela M Pollock, et al.
Molecular Cancer Research : MCR|September 30, 2008
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2Yasir H Ibrahim, Sara A Byron, Xiaojiang Cui, et al.
Nature Reviews. Genetics|March 22, 2016
Translating RNA sequencing into clinical diagnostics: opportunities and challengesSara A Byron, Kendall R Van Keuren-Jensen, David M Engelthaler, et al.
Molecular Cancer|October 9, 2012
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusSara A Byron, David C Loch, Candice L Wellens, et al.
Gynecologic Oncology|January 29, 2010
FGFR2 mutations are rare across histologic subtypes of ovarian cancerSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Plos One|March 3, 2012
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological featuresSara A Byron, Michael Gartside, Matthew A Powell, et al.
Pageof 4